Slides
Page 1
With the mission to cure type 1 diabetes NASDAQ First North Growth Market, ticker: DMYD B
Page 2
Disclaimer This Presentation (”Presentation”) has been prepared by Diamyd Medical AB (“Diamyd” or “the Company”). By accepting this Presentation, the recipient acknowledges and agree to the following: The information contained herein have been prepared to assist interested parties making their own evaluations of the Company and does not purport to be all-inclusive, or to contain all the information that the prospective investor may desire. In all cases the interested parties should conduct their own investigations and analyses of the Company, and the data set forth in this Presentation. Diamyd does not make any representation or warranty as to the accuracy or completeness of the information contained in this Presentation. Diamyd expressly disclaim any and all liability based on, or relating to, any representations or warranties contained in, or errors or omissions from, this Presentation or any other written or oral communications transmitted to the recipient, or any of its affiliates, or representatives, in the course of its investment evaluation of the Company.
Page 3
• Clinical development program, retogatein - targeting 40 % of type 1 diabetes • Phase 3 program: Stage 3 type 1 diabetes • Phase 2 program: Stage 1 & 2 type 1 diabetes • Discovery platform - targeting additional 50 % of type 1 diabetes • Precision medicine ecosystem: AI driven risk prediction, disease screening, and in-house biologics manufacturing • Antigen-specific immunotherapy targeting genetic subgroups • Durable disease-modifying effect and favorable safety profile based on 16 trials and more than 1,000 treated patients • Potential to extend health and life span by lowering risk for cardiovascular disease and other long-term complications • >$2 billion sales potential in the US alone for retogatein launch indication • Significant upsides: Rest of world, adult-onset Type 1 Diabetes (LADA), Stage 1 and 2 type 1 diabetes • FDA Fast Track and Orphan Drug Designation, alignment for an accelerated approval pathway • Phase 3 interim efficacy readout March 2026 to support potential accelerated BLA, full readout ~Q2 2027 Precision medicine for type 1 diabetes Therapeutic preservation of pancreatic function for early reversal and treatment Validated, de-risked immunology platform Strong regulatory alignment and milestones Precision medicine - reversal and intervention • 30+ years of Scientific and Clinical development • NASDAQ First North Growth Market, ticker: DMYD B • Market Cap February 6 2026 ~ MSEK 2 250; Cash Nov 31, 2025, MSEK 233 Corporate Status & Financials
Page 4
Significant unmet medical need and economic burden T1Dindex.org; Healthadvances 2020; IDF Atlas 2022; Rafshani et al 2019, Lancet High risk for serious complications incl. cardiovascular disease >500 000 new cases of type 1 diabetes annually 15 years shorter life span 35 years shorter health span Life long dependence on insulin treatment and blood glucose measurements >$90 billion economic burden
Page 5
. Genetic risk Environment Genetic risk1) Diamyd Medical addresses the full spectrum of type 1 diabetes Stage 1 Stage 2 Stage 3 Long-term T1D2) Autoimmunity Normal blood glucose No symptoms Autoimmunity Abnormal blood glucose No symptoms Autoimmunity Elevated blood glucose Symptoms Autoimmunity Long-term treatment Complications Healthy beta cells 1) Sometimes referred to as Stage 0. 2) Sometimes referred to as Stage 4. Insulin production Type 1 diabetes Insulin dependency Type 1 Diabetes Asymptomatic autoimmunity, incipient deficiencies in blood glucose monitoring and clinical diagnosis requiring lifelong insulin therapy
Page 6
Preserving pancreatic function Addressing the autoimmune destruction of insulin producing cells Insulin is a hormone needed for cells to take up glucose from the blood and use it as energy. Pancreas C-peptide is released in the same amount as insulin and can be measured with a simple blood test. Proinsulin Insulin- producing beta cells Insulin C-peptide • Therapeutic targeting of the autoimmune destruction of insulin-producing beta cells in the pancreas. • Preserving pancreatic function (endogenous insulin/C-peptide production) is associated with: • Better glycemic control • Fewer complications →Potential to extend health and lifespan by lowering risks of cardiovascular disease and long-term complications.
Page 7
Program Discovery Preclinical Phase 1 Phase 2 Phase 3 Status retogatein (rhGAD65) Additional beta cell antigens (including insulin) Type 1 diabetes, Stages 1–3 (including HLA DR4-DQ8 positive) Type 1 diabetes, Stage 3 (HLA DR3-DQ2 positive) Orphan Drug Designation; Fast Track Designation Type 1 diabetes, Stages 1–2 (HLA DR3-DQ2 positive) Fast Track Designation DIAGNODE-3 DiaPrecise Ongoing in the EU and US, early readout expected around March 2026 Started Q4 2023 Pipeline overview Targeted treatment across all stages of type 1 diabetes through HLA-specific antigen therapies
Page 8
Retogatein - Recombinant Glutamic Acid Decarboxylase (GAD) formulated in Alum (rhGAD65/alum) Therapeutic preservation of pancreatic function for early reversal and treatment • Preserve function of the pancreas (endogenous insulin production) • Delay or prevent disease progression • Reduce or prevent short- and long-term complications • Three targeted intranodal injections one month apart, outpatient treatment • Induce immunological tolerance against GAD65 • No immunosuppression• Phase 3 – Stage 3 type 1 diabetes • Phase 2 – Stage 1 & 2 type 1 diabetes • Phase 2 - Adult-onset type 1 diabetes / LADA • Type 1 diabetes (Stage 3) with residual beta cell function and HLA type DR3-DQ2 • Fast Track and Orphan Drug Designation • Type 1 diabetes prevention (Stage 1 & 2 with HLA type DR3-DQ2), Fast Track Designation • Adult-onset type 1 diabetes / LADA Primary Indication Primary Label Expansion Clinical Effect and Benefit Mechanism of Action Mode of Administration Development Status Licensing Status • Global rights wholly owned by Diamyd Medical
Page 9
GAD HLA presents GAD T cell receptor Antigen-presenting cell Auto-reactive T cell HLA is central to autoimmunity against GAD Retogatein targets autoimmunity against dominant antigen Genetically validated precision medicine approach Retogatein (rhGAD65) targets the GADA-first type 1 diabetes endotype with HLA DR3-DQ2 positivity representing approximately 40% of of those living with type 1 diabetes Responds to treatment HLA DR3-DQ2 genotype Newly diagnosed type 1 diabetes Individuals with newly diagnosed type 1 diabetes with HLA DR3-DQ2 present are selected for Phase 3 trial with rhGAD65
Page 10
IAA-first disease • HLA DR4-DQ8 (60%) • Enterovirus B • INS , PTPN22, UBASH3A • Likely responders to an insulin-based antigen-specific therapy GADA-first disease • HLA DR3-DQ2 (40%) • Adenovirus F • BACH2 • Likely responders to Diamyd® Age of auto-antibody occurrence Retogatein (rhGAD65) responders* Courtesy of Prof. Åke Lernmark. Graphs based on data from the TEDDY study *Identified and confirmed through retrospective and prospective clinical studies. Genetically validated precision medicine approach Retogatein (rhGAD65) targets the GADA-first type 1 diabetes endotype with HLA DR3-DQ2 positivity
Page 11
Regulatory & Commercial strategy
Page 12
• Fast Track Designation from the U.S. FDA for the treatment of Stage 1, 2 & 3 type 1 diabetes with HLA DR3-DQ2 • Aligned with both FDA and EMA • Alignment with the FDA • Interim readout to support potential accelerated BLA March 2026 • C-peptide as the primary endpoint for accelerated BLA • Full readout ~Q2 2027 to support a potential full BLA Pathway to market for retogatein (rhGAD65) Therapeutic preservation of pancreatic function for early reversal and treatment Single pivotal Phase 3 trial (DIAGNODE-3) Accelerated approval potential Fast Track Designation • Orphan drug designation from the U.S. FDA for the treatment of type 1 diabetes with residual beta cell function Orphan Drug Designation
Page 13
• Ex-US sales • Life Cycle Management – Stage 1, 2 type 1 diabetes, adult-onset type 1 diabetes / LADA, booster courses • Adult-onset type 1 diabetes / LADA base case US peak sales estimated at > $2 billion (in addition to launch indication LADA can add an additional $ 2 billion in sales) • 60k+ patients (Stage 3 Type 1 Diabetes with residual beta cell function, HLA DR3-DQ2 positive, age >= 12) • Estimated gross prices ~ $150k – 240k • Limited Gross-to-Net discounts • High type 1 diabetes insurance coverage and expected high prior authorization • Untapped market opportunity Estimated > $2 billion peak sales in the US alone Note: Base case assumptions informed by US payer and HCP Research Nov-24 Retogatein (rhGAD65) launch indication US Pricing, formulary status & market share Significant Upsides
Page 14
• US BLA approval provides 12 years exclusivity from market approval • US Orphan Drug Designation provides 7 years exclusivity from market approval • European approval provides 10 years of exclusivity from market approval • Composition of matter in the US until 2032 • Intralymphatic administration of retogatein (rhGAD65) in Europe, Japan, China, Hong Kong, Australia, South Africa, Eurasia and Canada, additional countries pending, expiry 2035 • Intralymphatic administration of additional betacell antigens (proinsulin, preproinsulin etc) approved in Australia, Israel, Russia, additional countries pending • Treatment/early reversal of HLA DR3-DQ2 subgroup with retogatein (rhGAD65) approved in Europe, Eurasia, Israel, Hong Kong, South Africa, Japan, South Korea, expiry 2038, additional countries pending • Treatment/early reversal of HLA DR4-DQ8 with insulin as an antigen approved in Europe, South Korea, Eurasia, expiry 2038, and pending in several territories Strong IP position and regulatory exclusivity Core Intellectual Property* Regulatory exclusivity *Subject to any applicable patent term adjustments
Page 15
Competitive positioning Based on late-stage development, unique modality and favorable safety profile The illustration shows examples of mainly company-driven projects in the field and is representative of the ongoing development, though not exhaustive. Diamyd Medical is at the forefront of the development of disease- modifying treatments for type 1 diabetes. Phase 1 Phase 2 Phase 3 Market Insulin-based antigens3 retogatein (rhGAD65) 3retogatein (rhGAD65) 1 2 Antigen combinations3 CAR/TCR Tregs 3 Coxackie virus vaccine 0 mTO<R inhibitor 3 Genetically modified islet-cells 4 Tolerogenic DCs3 Polyclonal T-reg cells 2 Anti-CD2 mAB3 Anti-TNF/Anti-OX403 CD40L mAB3 ATG3 Mesenchymal stem cells 0 Calcium channel blocker 3 Menin inhibition 3 GLP-1 / GIP agonist 3 Encapsulated insulin-producing cells; with immunosuppression 4 Zimislecel (stem-cell derived islet cells; with immuno- suppression) 4 TZIELD® (anti-CD3 mAB) 3 Baricitinib (JAK inhibitor) 2 3 TZIELD® (anti-CD3 mAB) 2 Lantidra (allogenic islet cells); with immuno- suppression) 4 Cell-replacement and non-disease- modifying Low specificity High specificity 0Stage: Stage 0 and Stage 4 are most often referred to as genetic risk and long-term type 1 diabetes. Specificity refers to how precisely a treatment targets the root cause of the disease. 1 2 3 4
Page 16
• Studies across Stage 1 & Stage 2 type 1 diabetes, adult-onset type 1 diabetes (LADA): appr. 10% type 2 diabetes • Potential for full-spectrum growth across type 1 diabetes • Subcutaneous product development opportunities (data available) • Extended pediatric use (lower age groups) • Dose-response demonstrated • Boosters feasible and safe • Potential for differentiation, new label claims, cumulative revenue, remission-level disease modification • HLA genetics central to efficacy • Potential for enhanced pricing strategy, market segmentation, remission-level disease modification Life-cycle management opportunities Retogatein offers unique opportunities to drive innovation, expand reach and maximize impact throughout the product life cycle Potential for regular boosters Genetic personalization & optimization Label expansion • Unique and specific MoA • Favorable safety across >1,200 treated individuals • Potential for cornerstone role in combo regimens, e.g. GLP1:s Combination therapies
Page 17
Clinical Data Supporting launch indication retogatein (rhGAD65)
Page 18
First in class, best in class and disease modifying Clinical summary of retogatein (rhGAD65) in Stage 3 type 1 diabetes • DIAGNODE-3 is a pivotal trial to confirm benefit of retogatein (rhGAD65) vs placebo on C-peptide and HbA1c in individuals with HLA DR3-DQ2, using IL administration • Strong safety profile (1,278 patients treated with retogatein; no safety issues) • Interim efficacy read-out end of March 2026; potential for accelerated approval • Meta-analysis of clinical trials in the subcutaneous program leads to identification of responder population (individuals with HLA DR3-DQ2) • DIAGNODE-2 trial showed higher preservation of C-peptide vs placebo in individuals with HLA DR3-DQ2 (pre-specified analysis) using intralymphatic (IL) administration Discovery Proof-of-concept Confirmation
Page 19
Favorable safety and tolerability profile Retogatein (rhGAD65) in Stage 3 type 1 diabetes • No new or unexpected safety signals noted • No suspected unexpected serious adverse reactions (SUSAR) reported in conjunction with intralymphatic (IL) administration (1 SUSAR in total, reported in adult type 1 diabetes patient) • Most common adverse events: transient tenderness, redness and edema at injection site • <2% subject drop-out rate in trials with IL administration • Safety profile assessed in clinical trials that included persons aged 4–70 years, with Stage 1– 3 type 1 diabetes Summary of clinical safety data 692 PATIENTS Total patient exposure in 16 trials1 Patient drop-out rate in clinical trials 1,278 PATIENTS Retogatein (rhGAD65)Placebo 1) November 2025. 2) CenterWatch, "Recruitment Rates Rising, but Retention Rates Fall, According to New Study" (February 2, 2020) by Leslie Ramsey. 4% 2% 12% 7% 0% 5% 10% 15% Retogatein – total Retogatein – intralymphatic administration Vaccines in general 2) Metabolic and cardiovascular diseases 2)
Page 20
Meta-analysis of genetic responder group Meta-analysis of 3 randomized controlled clinical trials with subcutaneous retogatein (rhGAD65) conducted before 2014 with >500 individuals identified patients carrying HLA DR3-DQ2 gene as responders 44% reduction in C-peptide* decline from Baseline to Month 15 compared to placebo in patients carrying the HLA DR3- DQ2 gene who received 3 or 4 injections of retogatein (rhGAD65) *C-peptide measures endogenous insulin production Significant treatment effect in subgroup of patients positive for HLA DR3-DQ2 gene (responder patients) 1 2 High dose = 3 or 4 injections; Low dose = 2 injections; Combined = 2, 3 or 4 injections Mixed meal tolerance test (MMTT) stimulated C-peptide Even larger treatment effect in ca. 50% of responder patients with HLA DR3-DQ2 who lack the HLA DR4- DQ8 gene (super responder patients) 2 Hannelius et al. Diabetologia 2020 1
Page 21
DIAGNODE-2 Phase 2b trial confirmed responder patients European, multinational, randomized, placebo-controlled, 2-arm trial assessing 3 targeted injections of retogatein (rhGAD65) given on top of standard of care rhGAD65*Screen Run-in Placebo 3 monthly intralymphatic injections *4 µg / inj, supplemented with oral Vitamin D 0 2 6 15 24 Follow-up Open-label extension** **Subgroup of patients (50 out of 109) Primary Endpoint • Change from Baseline to Month 15 in Mixed Meal Tolerance Test (MMTT) stimulated C-peptide Area under the Curve Key Secondary Endpoint • Change in Hemoglobin A1c (HbA1c) between baseline and Month 15 • Change in insulin-dose-adjusted HbA1c (IDAA1c) between Baseline and Month 15 • Change in daily exogenous insulin consumption between Baseline and Month 15 Population • Persons diagnosed with type 1 diabetes less than 6 months ago aged 12-24 years and positive for GAD antibodies • Residual beta cell function: fasting C-peptide ≥ 0.12 nmol/L • Pre-specified subgroup added to topline readout before database lock: responder patients with HLA DR3-DQ2 genotype months
Page 22
DIAGNODE-2 Phase 2b trial confirmed responder patients Ludvigsson et al. Diabetes Care 2021 Retogatein (rhGAD65) achieved statistically significant 56% preservation of C-peptide secretion, numerical improvement in HbA1c compared to placebo at Month 15 in patients with HLA DR3-DQ2. favours Retogatein favours Placebo favours Retogateinfavours Placebo
Page 23
DIAGNODE-2 Phase 2b trial confirmed responder patients In exploratory analyses, retogatein (rhGAD65) achieved statistically significant benefit on Continuous Glucose Monitoring (CGM) outcomes in patients carrying the HLA DR3-DQ2 responder gene Time in Range Glycaemic variability Time in severe hyperglycaemia % change from Baseline to Month 15 >250 mg/dL (>13.9 mmol/L) % change from Baseline to Month 15 Change in standard deviation from Baseline to Month 15 Independent Commentary by Lunati & Fiorina, JCEM 2022 Nowak et al. JCEM 2022 • Better Time in Range • Less time in severe hyperglycaemia • Less glycaemic variability
Page 24
DIAGNODE-2 Phase 2b trial biomarker data support HLA-specific response GAD-specific immune response differentiates responders from non-responders Median change from baseline of anti-GAD65 antibodies (GADA) and Proliferation of PMBC (Stimulation Index, SI) (A), and GAD-stimulated secretion by PBMC of IL-10 and IL-13 levels (B) for GAD-alum treated subjects with and without the DR3-DQ2 haplotype Placebo treatment subjects. P values, Wilcoxon test, are indicated. 0 3 6 9 12 15 0 500 1000 0 2 4 6 8 20000 40000 60000 Months GADA (mean change from baseline, IU/ml) Proliferation SI (mean change from baseline) GADA GAD-alum DR3-DQ2 (n=29) GADA GAD-alum Not DR3-DQ2 (n=27) GADA Placebo (n=52) Pr SI Placebo (n=52) Pr SI GAD-alum Not DR3-DQ2 (n=27) Pr SI GAD-alum DR3-DQ2 (n=29) # * * * * * * * * * * * * p<0.001 for difference to Placebo # p=0.0210 for difference between DR3-DQ2 and Not DR3-DQ2 groups 0 3 6 9 12 15 0 25 0 10 20 30 200 400 600 Time (months) GAD-stimulated IL-13 (change from baseline, pg/mL) GAD-stimulated IL-10 (change from baseline, pg/mL) IL10 GAD-alum DR3-DQ2 (n=29) IL10 GAD-alum Not DR3-DQ2 (n=27) IL10 Placebo (n=52) IL13 GAD-alum DR3-DQ2 (n=29) IL13 GAD-alum Not DR3-DQ2 (n=27) IL13 Placebo (n=52) # ## * * * * * * * * * * p<0.0001 for difference to Placebo # p=0.0095 for difference between DR3-DQ2 and Not DR3-DQ2 groups ## p=0.0080 for difference between DR3-DQ2 and Not DR3-DQ2 groups
Page 25
Ultrasound-guided targeted injection Quick, low-key outpatient procedure with discomfort comparable to venepuncture. Targets superficial lymph node to enhance immunological response • Procedure performed by a radiologist or endocrinologist with ultrasound training • Pain level equal to taking a blood sample • No pre-medication (only local anesthetic) Intralymphatic administration (seconds) Treated patient Ultrasound (minutes) Appointment Intralymphatic (IL)-injection with needle placed in plan with the ultrasound probe Monitoring of IL injection using ultrasound Flory, S. et al(2024).Allergy, 79(8), 2222–2234
Page 26
Partner since 2023 The first ever precision medicine Phase 3 trial in type 1 diabetes Retogatein (rhGAD65) in individuals recently diagnosed with Stage 3 type 1 diabetes and positive for the HLA DR3-DQ2 haplotype
Page 27
rhGAD65*Screen Run-in 2:1 rand. Placebo 3 monthly injections Supplementation with oral Vitamin D in both arms for D-vitamin deficient study participants 0 2 6 15 Follow-up • Interim analysis in March 2026, ~170 patients and 15-month follow-up to support a potential Accelerated BLA in the US • Primary readout, ~310-320 patients and 15-month follow-up to support full-BLA • Long-term durability readout at 24 months 24 DIAGNODE-3 single pivotal precision medicine Phase 3 trial Randomized, placebo-controlled, 2-arm trial to confirm the effect and safety of 3 targeted injections of retogatein (rhGAD65) given on top of standard of care. Design aligned with the FDA and EMA. 57 clinics in the United States and Europe. Co-Primary Endpoints • Stimulated C-peptide area under the curve, change from Baseline to Month 15 in Mixed Meal Tolerance Test (MMTT) • HbA1c, change from Baseline to Month 15 Key Secondary Endpoint • Time in glycemic target range 3.9-10 mmol/L (70-180 mg/dL) assessed by CGM, change from Baseline to Month 15 • Proportion of patients with insulin dose-adjusted HbA1c (IDAA1c) ≤9 (partial remission) at Month 15 • Number of episodes per patient of severe hypoglycemia between Baseline and Month 15 • Number of episodes per patient of diabetic ketoacidosis (DKA) between Baseline and Month 15 Population • Persons diagnosed with type 1 diabetes less than 6 months ago aged 12-29 years who are positive for GAD antibodies and positive for HLA DR3-DQ2 • Residual beta cell function: fasting C-peptide ≥ 0.12 nmol/L months *4 µg / inj, supplemented with oral Vitamin D
Page 28
Significant momentum and near-term clinical and regulatory catalysts March 2022 Phase 3 starts DIAGNODE-3 is initiated in Europe and expands to the US in September 2023 March 2026 Interim efficacy readout ~170 patients, 15 months. Potential for accelerated approval. Interim readout, aligned with the FDA February – June 2024 Fast Track Stage 1,2 & 3 Type 1 Diabetes FDA grants Fast Track Designation for retogatein (rhGAD65) across all stages of type 1 diabetes July 2024 Positive non-futility analysis DSMB recommendation to continue the trial unmodified July 2024 Accelerated pathway FDA acknowledges in Type C meeting C-peptide as surrogate endpoint for accelerated approval for retogatein (rhGAD65) ~Q2 2027 Primary full readout ~310-320 patients, 15 months ~Q1 2028 Long-term durability readout, ~310-320 patients, 24 months
Page 29
Supportive Clinical Data Stage 1 & 2 type 1 diabetes and adult-onset type 1 diabetes (LADA)
Page 30
Clinical data in Stage 1 and Stage 2 type 1 diabetes Long-Term follow-up of DiAPREV-IT shows that two subcutaneous injections of retogatein (rhGAD65) may delay type 1 diabetes onset by nearly 7 years Poster presented at ISPAD 2024, unpublished . KM plot of time to Type 1 Diabetes in HLA DR3-DQ2 (Diamyd ® n=12, Placebo n=15). The arrow highlights the difference in median time to stage 3 Type 1 Diabetes. Performed in 2024 based on data from the Swedish National Diabetes Registry combined with phone interviews. The study was performed by Prof. Helena Elding Larsson, Lund University. DiAPREV-IT: 2 subcutaneous injections of retogatein (rhGAD65) in 50 children positive for two or more islet autoantibodies. Analysis shows that 2 subcutaneous injections of retogatein (rhGAD65) may delay type 1 diabetes onset by nearly 7 years in children with the HLA DR3-DQ2 genotype – reinforcing its preventive potential and precision medicine approach.
Page 31
Phase 2 trial with retogatein in up to 70-year-old LADA patients 1-year pilot study of targeted injections of retogatein (rhGAD65) in individuals with adult-onset type 1 diabetes (latent autoimmune diabetes in adults (LADA)). No safety concerns. . Hals et al., Diabetes, Obes Metab. 2023 Glucagon-stimulated C-peptide * p< 0.03 for median 13.3% reduction at 12 months vs. Baseline (0 months) in the DR3DQ2 negative subgroup (n=7). * p< 0.04 for difference between HLA subgroups in change at 12 months vs. Baseline (0 months). Unchanged glucagon- stimulated C-peptide levels at 12 months vs Baseline (0 months) in the HLA DR3-DQ2 positive subgroup 0 5 12 0 5 12 80 85 90 95 100 DR3DQ2 positive (n=7) DR3DQ2 negative (n=7) Months Levels vs. Baseline (%) * *
Page 32
Manufacturing of retogatein (rhGAD65) Wholly-owned biomanufacturing plant
Page 33
Biomanufacturing facility - retogatein (rhGAD65) • 24,000 square feet facility, comprising clean rooms, laboratory facilities and office space • Commercial-scale production of retogatein (rhGAD65) to be ready for BLA/MAA and market entry • GMP certification of facility ongoing • Independence from CDMOs, third parties • In control of costs and resource allocation • Potential beyond GAD manufacturing Commercial-scale production Umeå, Sweden
Page 34
Manufacturing process Diamyd Medical’s biomanufacturing facility in Umeå uses the Baculovirus Expression Vector System (BEVS) in the complex manufacturing process of recombinant human GAD65 protein • Baculovirus expression system • Insect cells • Clarification • Capture • Polish • Nanofiltration • rhGAD65/alum • Formulated externally
Page 35
Team with extensive experience from biotech and pharma including Horizon Pharma, GSK, Genentech, Johnsson & Johnsson, Sanofi, Astra Zeneca Management Scientific Advisory BoardBoard of Directors Dr. Ulf Hannelius, PhD, MBA President & Chief Executive Officer Martina Widman, MSc Chief Operating Officer Niklas Axelsson, MSc Chief Financial Officer Anton Lindqvist, MSc Chief Scientific Officer Dr Sofia Mayans, PhD Head of Manufacturing Site Professor Dr. Mark Atkinson, PhD (Chair) University of Florida Professor Dr. David Leslie, MB BS, MRCS, MD, FRCP , FAoP University of London Professor Dr. Åke Lernmark, MD, PhD Lund University Associate Professor, Dr. Emily Sims, MD Indiana University School of Medicine Dr. Alice Long, PhD Benaroya Research Institute, Seattle Anders Essen-Möller, MSc Chairman, Founder Erik Nerpin, LL.M. Vice Chairman Maria-Teresa Essen-Möller, MSc Dr. Torbjörn Bäckström, MD, PhD Dr. Mark Atkinson, PhD Dr. Karin Hehenberger, MD, PhD Dr. Karin Rosén, MD, PhD
Page 36
There’s no insulin like your own www.diamyd.com